Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cycloserine

FDA-approved product (capsule, oral), marketed as Seromycin.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cycloserine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Extrapulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB01

Repurposing investigation

Cycloserine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 4 lab records
  • M. tuberculosis: measured active in 0 of 2 lab records
Open Cycloserine in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cycloserine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ONE-P TMS First Responders

    NCT07773935 · start 2026-11-01

    Registered record
    Registry ID
    NCT07773935
    Conditions
    PTSD - Post Traumatic Stress Disorder
    Interventions
    D-Cycloserine (DCS); Placebo; Intermittent Theta Burst Stimulation (iTBS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2029-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTSD - Post Traumatic Stress Disorder
    InterventionD-Cycloserine (DCS); Placebo; Intermittent Theta Burst Stimulation (iTBS)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

    NCT07593222 · start 2026-09-01

    Registered record
    Registry ID
    NCT07593222
    Conditions
    Major Depression; Healthy Participants
    Interventions
    Sham iTBS; TMS; D-cycloserine; Dextromethophan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2031-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression; Healthy Participants
    InterventionSham iTBS; TMS; D-cycloserine; Dextromethophan +1 more
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)

    NCT07145866 · start 2026-07-02

    Registered record
    Registry ID
    NCT07145866
    Conditions
    Nicotine Dependence; Transcranial Magnetic Stimulation; Vaping; Smoking Cessation; Smoking (Tobacco) Addiction
    Interventions
    Varenicline; Transcranial Magnetic Stimulation; Transcranial Magnetic Stimulation Sham; Nicotine Cessation Counseling; D-cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-02
    Completion
    2028-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNicotine Dependence; Transcranial Magnetic Stimulation; Vaping; Smoking Cessation +1 more
    InterventionVarenicline; Transcranial Magnetic Stimulation; Transcranial Magnetic Stimulation Sham; Nicotine Cessation Counseling +1 more
    PhasePhase 4
    Registry statusRecruiting

  • 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

    NCT07198685 · start 2025-09-30

    Registered record
    Registry ID
    NCT07198685
    Conditions
    Treat to Target; Treatment Duration
    Interventions
    bedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2028-09-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreat to Target; Treatment Duration
    Interventionbedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin +2 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Medial Enhancement Technique for the Treatment of Old Femoral Neck Fractures

    NCT06713031 · start 2024-12-10

    Registered record
    Registry ID
    NCT06713031
    Conditions
    Fracture of Neck of Femur
    Interventions
    cannulated compression screws + iliac bone graft; DCS + medial support plate + iliac bone graft
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-12-10
    Completion
    2026-10-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFracture of Neck of Femur
    Interventioncannulated compression screws + iliac bone graft; DCS + medial support plate + iliac bone graft
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine

    NCT05994703 · start 2023-10-20

    Registered record
    Registry ID
    NCT05994703
    Conditions
    Smoking Cessation; Harm Reduction
    Interventions
    d-cycloserine; Juul e-cigarette
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-10-20
    Completion
    2026-01-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation; Harm Reduction
    Interventiond-cycloserine; Juul e-cigarette
    PhasePhase 2
    Registry statusCompleted

  • AIH for Spinal Cord Repair

    NCT03780829 · start 2020-02-25

    Registered record
    Registry ID
    NCT03780829
    Conditions
    SCI
    Interventions
    hypoxia; sham hypoxia; D-cycloserine; sham-NMDA agonist; exercise training
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2020-02-25
    Completion
    2026-02-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSCI
    Interventionhypoxia; sham hypoxia; D-cycloserine; sham-NMDA agonist +1 more
    PhaseEarly phase 1
    Registry statusTerminated

  • NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

    NCT03396068 · start 2019-12-01

    Registered record
    Registry ID
    NCT03396068
    Conditions
    Bipolar Depression; Suicidal Ideation
    Interventions
    NRX-101; Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-12-01
    Completion
    2024-12-31
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression; Suicidal Ideation
    InterventionNRX-101; Lurasidone HCl
    PhasePhase 3
    Registry statusUnknown

  • Lower Limb Function After Spinal Cord Injury

    NCT02635893 · start 2019-06-21

    Registered record
    Registry ID
    NCT02635893
    Conditions
    Spinal Cord Injury
    Interventions
    D-Cycloserine; Placebo; Training; Stimulation; Placebo Stimulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-06-21
    Completion
    2021-04-11
    Enrolment
    257

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury
    InterventionD-Cycloserine; Placebo; Training; Stimulation +1 more
    PhasePhase 4
    Registry statusCompleted

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Cycloserine rTMS Plasticity Augmentation in Depression

    NCT03511599 · start 2018-09-03

    Registered record
    Registry ID
    NCT03511599
    Conditions
    Major Depressive Disorder
    Interventions
    Cycloserine; Transcranial Magnetic Stimulation; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-03
    Completion
    2021-04-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionCycloserine; Transcranial Magnetic Stimulation; Placebo Oral Tablet
    PhasePhase 1
    Registry statusCompleted

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression

    NCT02772211 · start 2016-06

    Registered record
    Registry ID
    NCT02772211
    Conditions
    Treatment Resistant Depression
    Interventions
    Ketamine; D-cycloserine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2017-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Resistant Depression
    InterventionKetamine; D-cycloserine; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome

    NCT02687165 · start 2016-01-16

    Registered record
    Registry ID
    NCT02687165
    Conditions
    Post Treatment Lyme Syndrome (PTLS); Chronic Pain
    Interventions
    Milnacipran and D-cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2016-01-16
    Completion
    2017-01-16
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Treatment Lyme Syndrome (PTLS); Chronic Pain
    InterventionMilnacipran and D-cycloserine
    PhaseNot applicable
    Registry statusTerminated

  • D-Cycloserine and Virtual Reality Exposure Therapy

    NCT02933684 · start 2015-01-01

    Registered record
    Registry ID
    NCT02933684
    Conditions
    Social Anxiety Disorder
    Interventions
    Seromycin; Virtual Reality Exposure Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-01-01
    Completion
    2016-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Anxiety Disorder
    InterventionSeromycin; Virtual Reality Exposure Therapy; Placebo
    PhasePhase 2
    Registry statusWithdrawn